This bill directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to create an expedited review process—within 180 days—for biologics license application (BLA) supplements that add an apheresis collection device to an existing BLA at a location not previously licensed for that device. Under the new procedure the Secretary must approve eligible supplements within 30 days of submission unless the Secretary demonstrates either a location-specific safety/potency/purity concern or a systemic failure by the owner/operator to meet standards.
The statute narrows eligibility: the applicant must already hold a BLA for at least one site and either operate three or more FDA-registered locations under that license or be accredited and in good standing by an accreditation organization whose standards the Secretary finds meet or exceed applicable regulatory requirements. The bill aims to expand blood-collection capacity quickly; it also compresses FDA’s review timeline and delegates significant judgment about accreditation standards to the Secretary, creating operational and legal questions for regulators, blood centers, and accrediting bodies.
At a Glance
What It Does
Requires HHS/FDA to establish, within 180 days, an expedited process for approving BLA supplements that add an apheresis device at a new site, and mandates approval within 30 days unless FDA shows a site-specific safety issue or systemic compliance failure. It applies only to applicants that hold at least one BLA site and either operate 3+ registered locations or are accredited and in good standing.
Who It Affects
Directly affects licensed blood centers seeking to add apheresis collection capabilities at new locations, accrediting organizations that verify blood-collection operations, the FDA’s biologics review and inspection offices, and manufacturers/operators of apheresis devices.
Why It Matters
This creates a statutory fast-track for a narrow class of BLA supplements, potentially increasing blood-collection capacity faster than under current processes. It shifts weight to accreditation and to FDA’s judgment about site-specific versus systemic risks, altering compliance incentives and resource needs across regulators and industry.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill establishes a statutory, time‑bounded path for certain blood centers to add apheresis collection devices at locations that previously lacked approval for those devices. It is not a blanket fast-track for all license changes: it applies only to supplements submitted by an owner or operator that already holds a biologics license for at least one site and that either operates three or more FDA-registered locations under that license or has current, good‑standing accreditation from an organization the Secretary accepts.
The expedited process is a change to how FDA will handle a subset of BLA supplements rather than a new licensing category.
Implementation requires FDA to craft procedures within 180 days and to approve eligible supplements within 30 calendar days of submission unless the Secretary documents either (1) a specific safety, purity, or potency concern tied to the new location, or (2) a systemic failure by the owner/operator to meet standards that protect product quality at other licensed locations. Those two exceptions are the statutory safety valve; otherwise the agency has a short window to complete its review.
The bill does not articulate detailed evidence standards for the exceptions, nor does it prescribe how and when on‑site inspections must occur relative to the 30‑day clock.A key operational hinge is the accreditation alternative: owners who lack three approved locations can qualify if accredited and in good standing by an organization whose standards the Secretary determines meet or exceed regulatory requirements. That delegation makes accreditation a proxy for demonstrated quality and will give accrediting bodies real influence over who can use the fast-track.
At the same time, the compressed timeline reallocates burden to FDA to reconcile speed with its inspection and review practices, and it creates potential legal and practical friction over what counts as an adequate showing of safety risk when FDA seeks to deny or delay an application.
The Five Things You Need to Know
The Secretary must establish the expedited BLA-supplement process within 180 days of enactment.
FDA must approve an eligible supplement within 30 days of submission unless it identifies either a location-specific safety/purity/potency concern or a systemic failure by the owner/operator.
To use the expedited track, the applicant must hold at least one biologics license site and either operate three or more FDA-registered locations under that license or be accredited and in good standing by an accreditation organization approved by the Secretary.
The expedited process applies only to supplements seeking to add an apheresis collection device at a location not previously licensed for that device—not to other types of license changes.
The bill leaves the Secretary discretion to determine which accreditation organizations and standards 'meet or exceed' regulatory requirements and does not specify inspection timing relative to the 30-day review window.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the 'Boosting Lifesaving Operations, Opening Donation Centers Act' or the 'BLOOD Centers Act.' This is housekeeping but important for citation and internal references in agency guidance and rulemaking that may follow implementation.
Mandate to create expedited BLA-supplement process
Directs the Secretary (through the FDA Commissioner) to establish an expedited procedure—under the statutory authority for biologics licensing—specifically for supplemental applications from blood-center owners/operators that want to add an apheresis device at a location not previously licensed for that device. The provision requires FDA to write the procedural framework, but it does not prescribe detailed content such as submission checklists, evidence thresholds, or inspection protocols; those operational details will be set by FDA during implementation.
30‑day approval deadline and narrow exceptions
Imposes a hard 30‑day calendar deadline for approval of eligible supplements unless the Secretary makes an affirmative showing of either a specific, site-linked safety/purity/potency issue or a systemic failure by the owner/operator to meet standards at other licensed locations. Practically, this compresses review and shifts pressure onto FDA to document denials quickly. The provision does not define what documentation suffices for the 'showing' or whether failure to act within 30 days amounts to automatic approval—leaving room for interpretive or adjudicative disputes.
Eligibility criteria for expedited review
Sets two alternative tests: operator must hold a BLA for at least one site and either (A) have FDA approval for three or more registered locations under that license, or (B) be accredited and in good standing by an accreditation organization the Secretary accepts. This creates two pathways—scale (3+ sites) or demonstrated quality through accreditation—each with different compliance consequences. The Secretary retains authority to evaluate accreditation equivalency, giving HHS/FDA discretionary control over which accrediting bodies confer access to the fast-track.
Definitions
Defines key terms used in the section—'BLA' (biologics license application), 'blood center' (human blood donation center), 'expedited procedure', and 'Secretary' (HHS/FDA). These definitions limit the scope to human blood-donation centers and the existing biologics framework rather than broader device or donor‑screening statutes, which matters for interpreting inter-agency responsibilities (for example between CBER and CDRH).
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Multi-site blood centers with established BLAs — They gain a predictable, statutory pathway to add apheresis capability at new sites quickly, reducing lead time for expanding collection networks and responding to local shortages.
- Hospitals and patients in regions with limited apheresis access — Faster placement of collection devices can increase local supply of platelets and other components that rely on apheresis, improving clinical availability during spikes in demand.
- Apheresis device manufacturers and service providers — Shorter approval cycles for site additions can accelerate device placements and commercial deployment, improving sales velocity and reducing project timelines.
- Accrediting organizations that meet the Secretary’s standard — Accreditation becomes a valuable credential; approved accreditors and their members benefit from increased demand for accreditation and re-accreditation services.
Who Bears the Cost
- FDA (CBER and inspection teams) — The agency must design and run the expedited process within 180 days and meet frequent 30‑day review deadlines, stretching review and inspection resources and potentially requiring reprioritization of other workloads.
- Small or single-site blood centers without accreditation — Centers that lack 3+ registered locations and are not accredited will not qualify for the fast-track and may face competitive disadvantages and longer timelines to expand.
- Accrediting organizations — Organizations that seek Secretary recognition will face pressure to demonstrate standards meet or exceed regulatory requirements and may incur increased programmatic and legal scrutiny.
- State health departments and local inspectors — Faster site approvals may increase demand for on‑site compliance verification or require states to coordinate more quickly with federal reviewers, shifting workload without explicit funding.
Key Issues
The Core Tension
The bill pits the urgent, practical need to expand blood-collection capacity quickly against FDA’s responsibility to ensure product safety and facility compliance: accelerating approvals helps meet supply needs but compresses the agency’s ability to conduct thorough reviews and inspections; the statute delegates accreditation judgment to HHS as a partial substitute for lengthy reviews, yet accreditation is a proxy that may not capture every localized risk.
The bill creates a clear policy priority—speeding expansion of apheresis capacity—but leaves multiple consequential implementation choices to FDA. The 30‑day approval mandate is operationally aggressive: complex supplements often require review of manufacturing controls, donor procedures, and sometimes facility inspections.
The statute does not specify whether FDA may rely on prior inspection history, remote assessments, accreditor reports, or staggered post‑approval inspections to satisfy its assurance needs, so agency guidance will shape how much review actually occurs within the 30‑day window.
Delegating the accreditation-equivalency judgment to the Secretary concentrates power in HHS to define which accrediting bodies confer fast-track access. That increases the influence of private accreditors but also raises transparency and legal‑challenge risks if the Secretary’s determinations are opaque.
The two statutory exceptions (site‑specific safety concerns and systemic failure) are intentionally narrow language, but the bill does not detail evidentiary standards or appeal routes. That omission makes disputes over denials or missed deadlines likely candidates for litigation and administrative review, and it risks creating uneven outcomes across regions depending on FDA field office practices and resource constraints.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.